P/B
9,3
Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
$6.1B
Market Cap • 9/22/2026
2015
(11 years)
Founded
2018
(8 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
7,2
P/EBITDA
59,6
P/OCF
32,9
P/FCF
33,3
P/E
123,8
BVPS
8
EPS
0,6
Market Cap
Market Cap
6,1B
EV
5,6B
EV/Revenue
6,6
EV/EBITDA
54,6
EV/EBIT
55,5
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,6%
Total Yield
-0,6%
Payout
0%
Retained Earnings
-414,1M
Profitability
Gross Margin
89,8%
EBITDA Margin
12,1%
EBIT Margin
11,9%
Net Margin
9,6%
D&A/EBITDA
0%
R&D/Revenue
15,1%
Capex/Revenue
0,3%
Capex/D&A
118,8%
Capex/OCF
1,2%
SBC/OCF
22,7%
% PPE
1,2%
% Goodwill
0%
ROE
14%
ROIC
29,8%
Growth
CAGR Revenue 5Y
155,6%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
3,9
Quick Ratio
3,2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!